Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective

Estrogen receptor-positive (ER+) is the most common subtype of breast cancer. Endocrine therapy is the fundamental treatment against this entity, by directly or indirectly modifying estrogen production. Recent advances in novel compounds, such as cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), or...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernando, Cristina, Ortega-Morillo, Belén, Tapia, Marta, Moragón, Santiago, Martínez, María Teresa, Eroles, Pilar, Garrido-Cano, Iris, Adam-Artigues, Anna, Lluch, Ana, Bermejo, Begoña, Cejalvo, Juan Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345926/
https://www.ncbi.nlm.nih.gov/pubmed/34360578
http://dx.doi.org/10.3390/ijms22157812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345926/
https://www.ncbi.nlm.nih.gov/pubmed/34360578
http://dx.doi.org/10.3390/ijms22157812

Ejemplares similares